Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.
作者信息
Tausch Eugen, Close William, Dolnik Anna, Bloehdorn Johannes, Chyla Brenda, Bullinger Lars, Döhner Hartmut, Mertens Daniel, Stilgenbauer Stephan
机构信息
Department of Internal Medicine III, Ulm University, Ulm, Germany.
Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.
出版信息
Haematologica. 2019 Sep;104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19.
Abstract
摘要
相似文献
1
Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中的维奈托克耐药性与获得性突变
Haematologica. 2019 Sep;104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19.
2
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.复发性 Gly101Val 突变的获得使慢性淋巴细胞白血病患者对 Venetoclax 产生耐药性。
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
3
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.在 Venetoclax 治疗慢性淋巴细胞白血病的进展中，出现了 BCL2 多个突变与 Gly101Val 共存的情况。
Blood. 2020 Mar 5;135(10):773-777. doi: 10.1182/blood.2019004205.
4
Landscape of Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.维奈托克治疗复发/难治性慢性淋巴细胞白血病患者的真实世界队列中耐药突变的全景。
Int J Mol Sci. 2023 Mar 18;24(6):5802. doi: 10.3390/ijms24065802.
5
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.在对维奈托克耐药、对伊布替尼耐药且伴有BTK/PLCG2突变的慢性淋巴细胞白血病（CLL）患者中发现的新型BCL2突变。
Blood. 2020 Jun 11;135(24):2192-2195. doi: 10.1182/blood.2019003722.
6
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.BCL2作为慢性淋巴细胞白血病治疗靶点的潜力。
Expert Rev Hematol. 2018 May;11(5):391-402. doi: 10.1080/17474086.2018.1456332. Epub 2018 Mar 29.
7
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.BCL-2 与 venetoclax 复合物的结构揭示了耐药突变的分子基础。
Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.
8
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.接受维奈托克单药治疗的慢性淋巴细胞白血病患者凋亡机制中复发性基因组改变的鉴定
Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24.
9
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.BCL2 替代蛋白的表达与 venetoclax 治疗的 CLL 患者预后的关系。
Leuk Lymphoma. 2021 May;62(5):1129-1135. doi: 10.1080/10428194.2020.1861278. Epub 2020 Dec 17.
10
Genomics of Resistance to Targeted Therapies.靶向治疗耐药性的基因组学。
Hematol Oncol Clin North Am. 2021 Aug;35(4):715-724. doi: 10.1016/j.hoc.2021.03.004. Epub 2021 May 26.
引用本文的文献
1
Biotransformation and disposition of C-labeled sonrotoclax ([C]BGB-11417) in preclinical safety species and characterization of unique contribution from gut microbiome.C标记的索托罗司（[C]BGB-11417）在临床前安全性研究物种中的生物转化与处置以及肠道微生物群独特作用的表征
Cancer Chemother Pharmacol. 2025 Aug 20;95(1):82. doi: 10.1007/s00280-025-04803-7.
2
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.慢性淋巴细胞白血病中靶向治疗的耐药性：临床与诊断实践的现状及展望
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02662-y.
3
upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in rearranged lymphomas.通过极光激酶抑制实现的上调克服了重排淋巴瘤中对维奈托克的原发性耐药。
iScience. 2025 May 2;28(6):112584. doi: 10.1016/j.isci.2025.112584. eCollection 2025 Jun 20.
4
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.解析维奈托克耐药性：在分子时代探索HMA/维奈托克难治性急性髓系白血病的未来。
Cancers (Basel). 2025 May 7;17(9):1586. doi: 10.3390/cancers17091586.
5
Improving Treatment Options for Patients with Double Refractory CLL.改善双重难治性慢性淋巴细胞白血病患者的治疗选择
Cancers (Basel). 2025 Jan 27;17(3):430. doi: 10.3390/cancers17030430.
6
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention.探索多发性骨髓瘤中维奈托克耐药性的BCL2调控及上游信号转导：治疗干预的潜在途径
Blood Cancer J. 2025 Feb 5;15(1):10. doi: 10.1038/s41408-025-01215-x.
7
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.血液系统恶性肿瘤中的BCL-2抑制剂：预测反应的生物标志物及管理策略
Front Oncol. 2025 Jan 21;14:1501950. doi: 10.3389/fonc.2024.1501950. eCollection 2024.
8
Emergence of rearrangement and mutations in , , and associated with therapy resistance in chronic lymphocytic leukemia.慢性淋巴细胞白血病中与治疗耐药相关的 、 和 重排及突变的出现
EJHaem. 2024 Oct 8;5(6):1265-1268. doi: 10.1002/jha2.1024. eCollection 2024 Dec.
9
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism.在活跃的慢性淋巴细胞白血病克隆扩增过程中，BCL2蛋白逐渐下降：对维奈托克临床疗效的潜在影响及机制洞察
Lymphatics. 2024 Jun;2(2):50-78. doi: 10.3390/lymphatics2020005. Epub 2024 Mar 28.
10
BCL2i-Based Therapies and Emerging Resistance in Chronic Lymphocytic Leukemia.基于 BCL2 的治疗方法与慢性淋巴细胞白血病的新兴耐药性。
Cells. 2024 Nov 20;13(22):1922. doi: 10.3390/cells13221922.
本文引用的文献
1
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.维奈托克联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病的持续时间：MURANO Ⅲ期研究的治疗后随访结果，可消除微小残留病灶并延长生存。
J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.
2
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.复发性 Gly101Val 突变的获得使慢性淋巴细胞白血病患者对 Venetoclax 产生耐药性。
Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.
3
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.维奈托克治疗伴有 17p 缺失的慢性淋巴细胞白血病患者：来自 II 期关键性试验全人群的结果。
J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.
4
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病。
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
5
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.对维奈克拉耐药的潜在机制及克服耐药的策略。
BMC Cancer. 2017 Jun 2;17(1):399. doi: 10.1186/s12885-017-3383-5.
6
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
7
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.淋巴瘤中 BCL2 家族蛋白获得性突变导致对 BH3 模拟物 ABT-199 的耐药性。
Blood. 2014 Jun 26;123(26):4111-9. doi: 10.1182/blood-2014-03-560284. Epub 2014 Apr 30.
8
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.ABT-199，一种强效和选择性的 BCL-2 抑制剂，在发挥抗肿瘤活性的同时不影响血小板。
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
9
UCSF Chimera--a visualization system for exploratory research and analysis.加州大学旧金山分校奇美拉——一个用于探索性研究与分析的可视化系统。
J Comput Chem. 2004 Oct;25(13):1605-12. doi: 10.1002/jcc.20084.
Zotero 插件